Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

VSTMBullishIndustry NewsShort Term

High materiality8/10

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

StockNews.AIJul 22, 4:01 PM EDT1 source

Trading thesisImportance 8/10

Bullish near-term on VSTM if TARGET-D 202 NSCLC data show activity; catalysts through 2026.

AI summary

What happened and why it matters

Verastem Oncology announced the first patient dosing in TARGET-D 2022 (TARGET-D 202) evaluating VS-7375 at the 900 mg daily RP2D for KRAS G12D-mutated NSCLC, including a cohort with untreated brain metastases. The program aims to establish a registration-directed path across multiple KRAS G12D tumor types, with data updates anticipated in the second half of 2026 and Fast Track support potentially accelerating development.

First patient dosed in TARGET-D 202 NSCLC; RP2D 900 mg daily.
FDA Fast Track designations for VS-7375 in pancreatic cancer and NSCLC.
KRAS G12D NSCLC ~5% of NSCLC; no approved targeted therapies.
Data updates expected in second half of 2026 across TARGET-D trials.

Sentiment rationale

Near-term catalysts (first-patient dosing in TARGET-D 202, Fast Track designations) could drive upside if data show meaningful activity; however, failure risks remain high given early-stage data and KRAS G12D challenges.

Key facts

01
First patient dosed in TARGET-D 202 NSCLC; RP2D 900 mg daily.
02
TARGET-D 202 includes brain metastases cohort in untreated NSCLC.
03
KRAS G12D NSCLC ~5% of NSCLC; no FDA-approved G12D therapies.
04
VS-7375 is a dual ON/OFF KRAS G12D inhibitor; 3 TARGET-D trials advancing; update H2 2026.
05
FDA Fast Track designation secured for VS-7375 in pancreatic cancer and NSCLC.

Industry News

Category: Industry News / Corporate Developments. It highlights Verastem’s ongoing KRAS G12D program and strategic collaborations, signaling potential long-term value but with high clinical and regulatory risk.